OFIX Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -13.52% compared to Orthofix Medical's net margin of --. Orthofix Medical's return on equity of -22.96% beat Perspective Therapeutics's return on equity of --.

Orthofix Medical has a consensus price target of $24.30, signalling upside risk potential of 71.25%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 502.21%. Given that Perspective Therapeutics has higher upside potential than Orthofix Medical, analysts believe Perspective Therapeutics is more attractive than Orthofix Medical.

Orthofix Medical has a beta of 0.992, which suggesting that the stock is 0.759% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Orthofix Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Orthofix Medical pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Orthofix Medical quarterly revenues are $215.7M, which are larger than Perspective Therapeutics quarterly revenues of --. Orthofix Medical's net income of -$29.1M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Orthofix Medical's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Orthofix Medical is 0.68x versus 15.47x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Integra Lifesciences Holdings has a net margin of -13.52% compared to Orthofix Medical's net margin of 4.39%. Orthofix Medical's return on equity of -22.96% beat Integra Lifesciences Holdings's return on equity of -0.45%.

Orthofix Medical has a consensus price target of $24.30, signalling upside risk potential of 71.25%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $24.75 which suggests that it could grow by 47.23%. Given that Orthofix Medical has higher upside potential than Integra Lifesciences Holdings, analysts believe Orthofix Medical is more attractive than Integra Lifesciences Holdings.

Orthofix Medical has a beta of 0.992, which suggesting that the stock is 0.759% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.241, suggesting its more volatile than the S&P 500 by 24.12%.

Orthofix Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Orthofix Medical pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

Orthofix Medical quarterly revenues are $215.7M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $442.6M. Orthofix Medical's net income of -$29.1M is lower than Integra Lifesciences Holdings's net income of $19.4M. Notably, Orthofix Medical's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Orthofix Medical is 0.68x versus 0.80x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -13.52% compared to Orthofix Medical's net margin of -1226.82%. Orthofix Medical's return on equity of -22.96% beat VolitionRX's return on equity of --.

Orthofix Medical has a consensus price target of $24.30, signalling upside risk potential of 71.25%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 500.41%. Given that VolitionRX has higher upside potential than Orthofix Medical, analysts believe VolitionRX is more attractive than Orthofix Medical.

Orthofix Medical has a beta of 0.992, which suggesting that the stock is 0.759% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.463%.

Orthofix Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Orthofix Medical pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Orthofix Medical quarterly revenues are $215.7M, which are larger than VolitionRX quarterly revenues of $474.5K. Orthofix Medical's net income of -$29.1M is lower than VolitionRX's net income of -$5.8M. Notably, Orthofix Medical's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Orthofix Medical is 0.68x versus 34.16x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -13.52% compared to Orthofix Medical's net margin of -10.04%. Orthofix Medical's return on equity of -22.96% beat Xtant Medical Holdings's return on equity of -35.34%.

Orthofix Medical has a consensus price target of $24.30, signalling upside risk potential of 71.25%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 243.14%. Given that Xtant Medical Holdings has higher upside potential than Orthofix Medical, analysts believe Xtant Medical Holdings is more attractive than Orthofix Medical.

Orthofix Medical has a beta of 0.992, which suggesting that the stock is 0.759% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.

Orthofix Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Orthofix Medical pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Orthofix Medical quarterly revenues are $215.7M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. Orthofix Medical's net income of -$29.1M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, Orthofix Medical's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Orthofix Medical is 0.68x versus 0.58x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.